Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
109 hedge funds and large institutions have $442M invested in Taro Pharmaceutical Industries Ltd. in 2018 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 32 increasing their positions, 42 reducing their positions, and 26 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
14% less funds holding
Funds holding: 127 → 109 (-18)
15% less capital invested
Capital invested by funds: $521M → $442M (-$79.1M)
24% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 42
65% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 26
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $27K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.64M |
| 2 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$4.14M |
| 3 |
FCH
Freestone Capital Holdings
Seattle,
Washington
|
+$2.17M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.07M |
| 5 |
SCP
Seizert Capital Partners
Birmingham,
Michigan
|
+$1.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
-$17.1M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$8.1M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$8.09M |
| 4 |
MICM
Matthews International Capital Management
San Francisco,
California
|
-$5.51M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.1M |
TARO Hedge Fund Activity: Q1 2018 in Review
109 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q1 2018, worth a combined $442M — down 15% from $521M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of TARO and 9 opened new positions — a net loss of 17 holders — while 42 trimmed existing stakes and 32 added.
The largest buyer was Fidelity Investments, adding an estimated $6.64M. The largest seller was Schroder Investment Management Group, cutting an estimated $17.1M.
- 109 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q1 2018, down from 127 in Q4 2017.
- Funds reported $442M of Taro Pharmaceutical Industries Ltd. stock for Q1 2018, down 15% quarter-over-quarter.
- 9 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q1 2018 and 26 closed out, a net change of -17 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q1 2018 was Fidelity Investments, an estimated $6.64M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q1 2018 was Schroder Investment Management Group, an estimated $17.1M sold.
Based on aggregated 13F filings for Q1 2018.